A positron emission tomography study of quetiapine in schizophrenia: A preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy

Archives of General Psychiatry

Volumn 57, Issue 6, 2000, Pages 553-559

  Kapur, Shitij ^a,b   Zipursky, Robert ^a,b   Jones, Corey ^a   Shammi, C S ^a,b   Remington, Gary ^a,b   Seeman, Philip ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; PROLACTIN; QUETIAPINE; SEROTONIN 2A RECEPTOR;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HUMAN; POSITRON EMISSION TOMOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RECEPTOR OCCUPANCY; SCHIZOPHRENIA;

EID: 0034091239     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.57.6.553     Document Type: Article

References (42)

1. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 1976;261:717-719.
2. 2 receptors, yet occupy high levels of these receptors. Mol Psychiatry. 1998;3:123-134.
3. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996;124:57-73.
4. Pilowsky LS, O'Connell P, Davies N, Busatto GF, Costa DC, Murray RM, Ell PJ, Kerwin PW. In vivo effects on striatal dopamine D-2 receptor binding by the novel atypical antipsychotic drug sertindole: a 1231 IBZM single photon emission tomography (SPET) study. Psychopharmacology (Berl). 1997;130:152-158.
5. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992;49:538-544.
6. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156:286-293.
7. Nordstrom AL, Farde L. Plasma prolactin and central D-2 receptor occupancy in antipsychotic drug-treated patients. J Clin Psychopharmacol. 1998;18:305-310.
8. 2 occupancy, clinical response, and side effects: a double-blind PET study in first-episode schizophrenia. Am J Psychiatry. 2000;157:514-520.
9. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin-2 pKi values. J Pharmacol Exp Ther. 1989;251:238-246.
10. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153:466-476.
11. Puech A, Fleurot O, Rein W, for the Amisulpride Study Group. Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs haloperidol. Acts Psychiatr Scand. 1998;98:65-72.
12. Freeman HL. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies. Int Clin Psychopharmacol. 1997; 12(suppl 2):S11-S17.
13. Ogren SO, Hall H, Kohler C, Magnusson O, Lindhlom LO, Angeby K, Florvall L. Remoxipride, a new potential antipsychotic compound with selective antidopaminergic actions in the rat brain. Eur J Pharmacol. 1984;102:459-474.
14. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology. 1993;112:285-292.
15. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry. 1997;54:549-557.
16. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo: the Seroquel Trial 13 Study Group. Biol Psychiatry. 1997;42:233-246.
17. Peuskens J, Link CGG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand. 1997;96:265-273.
18. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
19. Tauscher J, Kufferle B, Asenbaum S, Brucke T, Kasper S. Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine. Psychopharmacology. 1997; 133:102-105.
20. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276.
21. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised. Rockville, Md: US Dept of Health, Education, and Welfare, National Institute of Mental Health; 1976. Publication ADM 76-338.
22. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154: 672-676.
23. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
24. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry. 1998;155:921-928.
25. 18F]setoperone: a new high-affinity ligand for positron emission tomography study of the serotonin-2 receptors in baboon brain in vivo. Eur J Pharmacol. 1988;147:73-82.
26. 18F-labeled setoperone. J Neurochem. 1990;54:1744-1754.
27. 18F]-setoperone PET imaging. Nucl Med Commun. 1997;18:395-399.
28. 18F]setoperone in neuroleptic-naive patients and normal subjects. Am J Psychiatry. 1999; 156:72-78.
29. Seroquel (quetiapine fumarate, ICI 204,636), An Atypical Antipsychotic [investigator's brochure]. Wilmington, Del: Zeneca Pharmaceuticals; 1997.
30. 2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology (Berl). 1998;135:119-126.
31. Stockmeier CA, DiCarlo JJ, Zhang Y, Thompson P, Meltzer HY. Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors. J Pharmacol Exp Ther. 1993;266:1374-1384.
32. Seeman P, Ulpian C. Neuroleptics have identical potencies in human brain limbic and putamen regions. Eur J Pharmacol. 1983;94:145-148.
33. Farde L, Suhara T, Nyberg S, Karlsson P, Nakashima Y, Hietala J, Halldin C. A PET study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology (Berl). 1997;133:396-404.
34. Pilowsky LS, Mulligan RS, Acton PD, Ell PJ, Costa DC, Kerwin RW. Limbic selectivity of clozapine [letter]. Lancet. 1997;350:490-491.
35. Andree B, Nyberg S, Ito H, Ginovart N, Brunner F, Jaquet F, Halldin C, Farde L. Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine-2A receptors in the human brain. J Clin Psychopharmacol. 1998;18:317-323.
36. Report S. Management decisions on priority pipeline products-MDL 100907 [press release]. In: Vision Extra, Vol 4. Frankfurt/Main, Germany: Hoescht Marion Roussel Global Employee Communications; July 22, 1999.
37. 2A antagonist fananserin in the treatment of schizophrenia. Am J Psychiatry. 1999;156:419-425.
38. 2 receptor occupancy [letter]. Arch Gen Psychiatry. 1998;55:666-668.
39. Lee HS, Song DH, Kim JH, Lee YM, Han ES, Yoo KJ. Cyproheptadine augmentation of haloperidol in chronic schizophrenic patients: a double-blind placebo-controlled study. Int Clin Psychopharmacol. 1995;10:67-72.
40. Nyberg S, Farde L, Halldin C, Dahl ML, Bertilsson L. D-2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. Am J Psychiatry. 1995;152:173-178.
41. Kapur S. Receptor occupancy by antipsychotics: concepts and findings. In: Lidow M, ed. Role of Neurotransmitter Receptors in Actions of Antipsychotic Medications. London, England: CRC Press; 1999: In press.
42. Kane JM. Drug therapy: schizophrenia. N Engl J Med. 1996;334:34-41.